Does hyperbaric oxygen therapy aid wound healing?

Hyperbaric Oxygen Therapy for Wound Healing

Consider hyperbaric oxygen therapy (HBOT) as an adjunctive treatment only for ischemic or neuro-ischemic diabetic foot ulcers that have failed standard wound care, and only where HBOT facilities already exist. For most other wound types, the evidence does not support its routine use.

Evidence-Based Recommendations by Wound Type

Diabetic Foot Ulcers (Ischemic/Neuro-ischemic)

The most recent 2024 IWGDF guidelines provide a conditional recommendation to consider HBOT specifically for neuro-ischemic or ischemic diabetes-related foot ulcers where standard care has failed 1. This represents a narrow, selective indication based on:

• Low certainty evidence from 18 RCTs, with only three being double-blinded
• Conflicting results, though the lowest risk-of-bias studies suggest potential benefit for wound healing
• No demonstrated reduction in amputation rates 1
• Moderate desirable effects on absolute wound healing and ulcer area reduction

Critical limitations to understand:

• Many patients cannot complete the full HBOT regimen due to poor overall health 2
• Requires assessment for suitability; patients with general frailty and comorbidities must often be excluded due to increased adverse event risk 1
• Requires weeks of intensive treatment with significant time burden
• Only feasible for patients living near established hyperbaric units

The 2020 IWGDF guidelines similarly recommended considering systemic HBOT as adjunctive treatment in non-healing ischemic diabetic foot ulcers despite best standard care (weak recommendation, moderate evidence) 2.

Important Contradictory Evidence

The 2019 and 2022 American Diabetes Association guidelines present a more skeptical view 3, 4:

• The Dutch DAMOCLES trial (high-quality RCT with 103 patients) found HBOT did not reduce amputation indication or facilitate wound healing compared to comprehensive wound care 3, 4
• Multiple subsequent studies failed to demonstrate benefit or had significant design flaws
• HBOT does not significantly affect health-related quality of life 3, 4
• Evidence remains "inconclusive regarding clinical and cost-effectiveness" 4

The ADA recommends HBOT should be a topic of shared decision-making rather than routine recommendation, despite Medicare coverage for ulcers failing 30 days of standard therapy 4.

Topical Oxygen Therapy

The 2024 IWGDF guidelines now conditionally recommend considering topical oxygen as adjunctive therapy where standard care has failed (conditional, low evidence) 1. This represents an upgrade from 2020 when it was not recommended 2.

• Three double-blinded RCTs with mixed results
• One low-risk-of-bias trial showed statistically significant complete wound healing at 12 weeks
• Another showed no difference from standard care
• No benefit demonstrated for amputation prevention 1

Other Wound Types

Venous Ulcers

• Insufficient evidence: Only one small trial (16 participants) showed benefit only at 6 weeks for ulcer area reduction 5

Pressure Ulcers

• Insufficient evidence to assess safety and efficacy 6
• Not recommended in ACP guidelines

Arterial and Other Chronic Wounds

• No trials identified for arterial ulcers 5
• Recent observational data (2023) showed 61% healing rate across mixed wound types with median 39 HBOT sessions, but this lacks controlled comparison 7

Practical Algorithm for Decision-Making

Use HBOT only if ALL criteria are met:

1. Wound type: Ischemic or neuro-ischemic diabetic foot ulcer
2. Failed standard care: No measurable healing after minimum 2-4 weeks of optimal standard care (debridement, offloading, infection control, vascular assessment)
3. Patient suitability:
   • Able to tolerate hyperbaric environment
   • No severe frailty or prohibitive comorbidities
   • Can commit to 30-40 sessions over weeks
4. Resource availability: Established HBOT facility exists (do not build new facilities for this indication)
5. Geographic feasibility: Patient lives close enough for repeated treatments

Do NOT use HBOT for:

• Non-ischemic diabetic foot ulcers
• Routine wound care without trial of standard therapy
• Venous ulcers (insufficient evidence)
• Pressure ulcers (insufficient evidence)
• When resources would need to be created specifically for wound treatment

Cost-Effectiveness Considerations

HBOT requires substantial costs (median €9,188 per treatment series) 7. Cost-effectiveness is only plausible where hyperbaric units already exist for other medical indications 1. Poor-quality cost studies fail to account for construction costs of new units 1.

Common Pitfalls to Avoid

1. Using HBOT too early: Standard care must be optimized first, including sharp debridement, appropriate offloading, infection management, and vascular assessment
2. Ignoring patient selection: Patients with severe arterial disease or inability to complete 30+ sessions have poor outcomes 7
3. Expecting amputation prevention: Evidence does not support reduced amputation rates 1
4. Applying to wrong wound types: Evidence is specific to ischemic diabetic foot ulcers

Adverse Effects

Most adverse effects are mild and transient 7:

• Fatigue
• Hyperoxic myopia (temporary vision changes)
• Middle ear barotrauma
• More serious complications possible in unsuitable patients

Bottom Line

HBOT has a very narrow, conditional role in wound healing—limited to ischemic diabetic foot ulcers failing standard care, where facilities already exist. The evidence quality is low, results are conflicting, and the most recent high-quality trials show no benefit. For the vast majority of wounds and clinical scenarios, HBOT should not be used.